A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis
- Butzkueven, Helmut (Primary Chief Investigator (PCI))
- Gibson, Peter (Chief Investigator (CI))
Project: Research